期刊文献+

弥漫大B细胞淋巴瘤患者治疗前FDG-PET/CT检查与预后的相关性分析 被引量:7

Correlation analysis of pre-therapy FDG-PET/CT with prognosis in patients with diffuse large B-cell lymphoma
原文传递
导出
摘要 目的:评估治疗前18氟-氟代脱氧葡萄糖-正电子发射计算机断层显像(18F-FDG-PET)/CT的最大标化摄取值(SUVmax)对弥漫大B细胞淋巴瘤(DLBCL)预后预测价值。方法:回顾分析76例新发DLBCL患者初次PET/CT检查中最大SUVmax与疾病分期、乳酸脱氢酶(LDH)、校正国际预后指数(R-IPI)等预后因素之间的相关性以及预后分析。结果:初发DLBL患者PET/CT的SUVmax与疾病分期、B症状、LDH、β2微球蛋白(β2-MG)、美国东部肿瘤协作组(ECOG)评分呈正相关。R-IPI3个预后组中的SUVmax有显著区别,R-IPI预后差的一组SUVmax均值明显高于前2组,有统计学意义(P<0.001)。SUVmax=10.25预测疾病进展的灵敏度和特异度分别是84.4%和68.2%。以此为标准分2组,SUVmax<10与SUVmax≥10组总有效率分别为87.9%和55.8%(P<0.05),3年PFS率分别是86.4%±6.4%和45.9%±9.8%(P=0.004),3年总生存(OS)率无统计学差异。经多因素Cox回归分析后显示IPI、LDH和SUVmax均为独立预后因素。结论:DLBCL患者治疗前PET/CT中FDG摄取强度可以预测患者的生存情况,SUVmax越低患者预后越好,反之,SUVmax越高患者预后越差。 Objective To assess the predictive value of pre-therapy 18fluoro-deoxyglucose positron emission tomography(18F-FDG-PET)/CT maximum standard uptake value(SUVmax) on prognosis in patients with diffuse large B-cell lymphoma(DLBCL).Methods The correlation between SUVmax of FDG-PET/CT and prognostic factors such as stage of disease,lactate dehydrogenase(LDH) level,revised international prognosis index(R-IPI) and the actual prognosis in 76 newly diagnosed DLBCL patients was analyzed retrospectively.Results FDG-PET/CT SUVmax was positive correlated with stage of disease,B symptom,LDH,β2 microglobulin(β2-MG) and East Cooperative Oncology Group(ECOG) score.Of the three R-IPI prognosis groups,SUVmax value of the poor prognosis group was significantly higher than the other two groups(P0.001).Taking SUVmax value 10.25 as the prognosis predictive threshold,the sensitivity and specificity were 86.4%±6.4% and 45.9%±9.8%(P0.001).Taking this as the cut-off value,the overall response rates in SUVmax10 group and SUVmax≥10 group were 87.9% and 55.8%,respectively;and the 3-year progress free survival(PFS) rates were 86.4%±6.4% and 45.9%±9.8%,respectively(P=0.004).However,no statistical significant difference was seen in 3-year overall survival(OS) rate.Multivariate Cox regress analysis showed IPI,LDH and SUVmax were independent prognostic factors.Conclusions Pre-therapy FDG-PET/CT SUVmax could predict the prognosis and survival of patients with DLBCL.The lower the SUVmax value,the better was the prognosis of patient.
出处 《内科理论与实践》 2011年第1期39-43,共5页 Journal of Internal Medicine Concepts & Practice
基金 浦东新区社会发展局重点协作项目(项目编号:PW2009D-5)
关键词 非霍奇金淋巴瘤 弥漫大B细胞淋巴瘤 FDG-PET 预后 Non-Hodgkin lymphoma Diffuse large B-cell lymphoma 18Fluoro-deoxyglucose positron emission tomography Prognosis
  • 相关文献

参考文献16

  • 1Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome [J]. J Nucl Med, 2005, 46(6): 983-995.
  • 2Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors [J]. J Nucl Med, 2009, 50 Suppl 1: 122S- 150S.
  • 3Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: eoregistered FDG PET and CT at staging and restaging do we need contrast-enhanced CT? [J]. Radiology, 2004. 232(3): 823-829.
  • 4lsasi CR. Lu P, Blaufox MD. A metaanalvsis of ^18F-2- deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma[J]. Cancer, 2005. 104(5): 1066-1074.
  • 5Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidenee base? [J]. Nuel Med Commun, 2007.28(5): 335-354.
  • 6Seam P. Juweid ME. Cheson BD. The role of FDG-PET seans in patients with lymphoma [J]. Blood, 2007, 110 (10): 3507-3516.
  • 7Schoder H, Nov A. G0nen M. et al. Intensity of ^18fluorodeoxyglueose uptake in positron emission tomography distinguishes between indolent and aggressive non- Hodgkin's lymphoma [J]. J Clin Oneol. 2005. 23(21): 4643-4651.
  • 8王学文.FDG-PET显像技术在恶性淋巴瘤诊断与治疗中的应用[J].现代肿瘤医学,2008,16(1):134-137. 被引量:4
  • 9Sehn LH. Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J]. Blood, 2007, 109(5): 1857-1861.
  • 10Cheson BD, Pfistner B. Juweid ME. et al. Revised response criteria for malignant tymphoma [J]. J Clin Oncol,2007, 25(5): 579-586.

二级参考文献31

  • 1小杉浩史.悪性リソパ腫診療にぉけるPETの役割[J].內科,2006,96(2):225-231.
  • 2Kostakoglu L, Goldsmith SJ. Fluorine - 18 fluorodeoxyglucose positron emission tomography in the staging and follow - up of lymphoma:Is it time to shift gears[J]? Eur J Nucl Med,2000,27(10) : 1564.
  • 3Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: Current status[ J ]. Oncologist ,2003,8 (3) :438-447.
  • 4Ell PJ. The contribution of PET/CT to improved patient management[J]. Br J Radiol,2006,79( 1 ) :32 -36.
  • 5Juweid ME. Utility of positron emission tomography(PET) scanning in managing patients with Hodgkin lymphoma [ M ]. Florida : Orlando ,2006. 259 -265.
  • 6Schaefer NG. Non - Hodgkin lymphoma and Hodgkin disease: FDG -PET and CT at staging and restaging[ J]. Radiology,2004, 232 (4) :823 -829.
  • 7Raanani P,Shasha Y,Perry C,et al. Is CT scan still necessary for staging in Hodgkin and non - Hodgkin lymphoma patients in the PET/CT era [J]. Ann Oncol, 2006,17(1 ) :117.
  • 8von Schuhhess GK, Steinert HC, Hany TF. Integrated PET/CT: Current applications and future directions[ J]. Radiology,2006,238 (2) :405 -422.
  • 9Buchmann I, ReinhardtM, Eisner K, et al. 2 - ( fluorine - 18 ) fluoro- 2 -deoxy -D -glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial [ J ]. Cancer,2001,91 (4) :889-899.
  • 10Hueltenschmidt B, Sautter -Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease[ J ]. Cancer,2001,91 ( 2 ) :302 - 310.

共引文献3

同被引文献82

  • 1Milutin Bulajic,Nikola Panic,Miodrag Radunovic,Radisav Scepanovic,Radoslav Perunovic,Predrag Stevanovic,Tatjana Ille,Maurizio Zilli,Mirko Bulajic.Clinical outcome in patients with hilar malignant strictures type Ⅱ Bismuth-Corlette treated by minimally invasive unilateral versus bilateral endoscopic biliary drainage[J].Hepatobiliary & Pancreatic Diseases International,2012,11(2):209-214. 被引量:9
  • 2周吉成.非霍奇金淋巴瘤治疗现状[J].广西医学,2005,27(10):1508-1509. 被引量:5
  • 3Juweid M E,Cheson B D.Role of positron emission tomography in [ymphoma[J].J Clin 0ncol,2005,23(21):4577-4580.
  • 4Yi J H, Kim S J, Choi J Y, et al. 'SF-FDG Uptake and its Clinical Relevence in Primary Gastric Lymphoma[J].Hematol Oncol,2009, 10.
  • 5Radan L, Fischer D, Bar-Shalom R, et aI,FDG Avidity and PET-CT Patterns in Primary Gastric Lymphoma[J]. Eur J Nucl Med MolImaging,2008,35(8):1424-1430.
  • 6Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-de- oxy-2-fluoro-D-glucose Positron Emission Tomography for Gastric Cancer[J].World J Surg,2004,28(3):247-253.
  • 7Schocler H,Noy A,Gonen M,et al,lntensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive nonHodgkin's lymphoma[J]. J Clin On- col, 2005,23(21 )4643 -4651.
  • 8Ngeow J Y, Quek R H, Ng D C, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma [J]. Ann 0ncol,2009,20(9):1543-1547.
  • 9No authors listed.A predictive model for aggressive non-Hodgkin's lymphomas.The International Non-Hodgkin's Lymphoma Prognostic Factors Project[J].N Engl J Med,1993,329 (14):987-994.
  • 10崔丽娟,白晓川.非霍奇金淋巴瘤预后相关因素分析[J].亍夏医科大学学报,2009,31(3)343-345.

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部